We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Daniel Catenacci

Daniel Catenacci MD

Associate Professor of Medicine, The University of Chicago Medicine, Chicago, Illinois

Recent Contributions to PracticeUpdate:

  1. FDA Approves Pembrolizumab for Advanced or Metastatic Esophageal/Gastroesophageal Junction Cancer
  2. Ivosidenib for Patients With IDH1-Mutated Cholangiocarcinoma
  3. ASCO GI: Adding Lenvatinib to Pembrolizumab in Patients With Advanced Gastric Cancer
  4. ASCO GI: New Data on FGFR Inhibition With Frontline Bemarituzumab in Gastroesophageal Tumors
  5. Adding Immunotherapy to First-Line Chemotherapy for Gastric Cancer: Data and Implications From ATTRACTION-4
  6. New Data on Adjuvant Treatment of Esophageal Cancer
  7. Adding Immunotherapy to First-Line Chemotherapy for Esophageal Cancer: Data and Implications From KEYNOTE-590
  8. Adding Immunotherapy to First-Line Chemotherapy for Gastric Cancer: Data and Implications From CHECKMATE 649
  9. Updated Results From an Observational Study of Nivolumab for Advanced Gastric Cancer
  10. Trastuzumab Deruxtecan for Patients With HER2-Positive Advanced Gastric or GE Junction Adenocarcinoma

Most Read This Week

Recently Updated